NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485

Phase 2 Completed 195 enrolled University of Rochester National Institute of Neurological Disorders and Stroke (NINDS) · collab

RandomizedDouble-blindTreatment

Summary

The goal of this study is to assess the impact of CoQ10 and GPI 1485 on the progression of Parkinson's disease, in order to determine whether it is reasonable to proceed with further study of either of these agents.

Timeline

Start: 2004-01
Primary completion: 2005-09
Completion: 2005-09

Publications

Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol. 2014 Jun;71(6):710-6. doi: 10.1001/jamaneurol.2014.391.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Coenzyme Q10	Other / unclassified	—	—
Subject	GPI 1485	Small molecule	—	—

NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485

Summary

Timeline

Publications

Drugs

Indications